To include your compound in the COVID-19 Resource Center, submit it here.

LY2127399: Phase I data

A dose-escalation Phase I trial in 20 patients with previously treated MM showed that IV LY2127399 plus IV bortezomib

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE